Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587764 | 1.00 | HSD17B10 (1.00) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| Ammonia Solution, Strong SCHEMBL1764035 | 0.98 | HSD17B10 (0.97) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6160546 | 0.98 | HSD17B10 (0.97) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| Ammonia Solution, Strong SCHEMBL8729935 | 0.86 | HSD17B10 (0.74) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2539061 | 0.85 | OPRM1 (0.77) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8729938 | 0.85 | HSD17B10 (0.72) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11880961 | 0.84 | HSD17B10 (0.73) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11593274 | 0.84 | HSD17B10 (0.73) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL318959 | 0.84 | HSD17B10 (0.73) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL3068674 | 0.84 | HSD17B10 (0.73) | HSD17B10OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | claimed |
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | claimed |
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | ZEALAND PHARMA A/S (DK) | 2008-11-20 | — | — | US | claimed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | claimed |
| US-20070072837-A1 | Phenylalkynes | APODACA RICHARD | 2007-03-29 | — | — | US | claimed |
| WO-2007019987-A1 | SUBSTITUTED 8-(3-AMINOPROPYL)-1-PHENYL-1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ON-DERIVATIVES FOR USE IN PAIN THERAPY | Grünenthal GmbH (DE) | 2007-02-22 | — | — | WO | claimed |
| EP-1451167-B1 | PHENYLALKYNES | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1628978-A2 | TRIAZA-SPIRO COMPOUNDS AS NOCICEPTIN ANALOGUES AND USES THEREOF | Zealand Pharma A/S (DK) | 2006-03-01 | — | — | EP | claimed |
| EP-1567494-A1 | METHODS FOR PREPARING PHENYLALKYNE DERIVATIVES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| EP-1558595-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037801-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20040002604-A1 | Phenylalkynes | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-01 | — | — | US | claimed |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003050099-A1 | PHENYLALKYNES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-20030040479-A1 | Rotational intrathecal analgesia method and device | OMEROS CORPORATION | 2003-02-27 | — | — | US | claimed |
| US-20030040486-A1 | Rotational intrathecal analgesia | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-02-27 | — | — | US | claimed |
| WO-2001039723-A2 | TRIAZOSPIRO COMPOUNDS HAVING NOCICEPTIN RECEPTOR AFFINITY | EURO-CELTIQUE, S.A. (LU) | 2001-06-07 | — | — | WO | claimed |
| EP-0359790-B1 | 1,4-BENZOXAZINE AND 1,4-BENZOTHIAZINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | claimed |
| US-4020072-A | PSYCHOTROPIC | E. R. SQUIBB & SONS, INC. (US) | 1977-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | OPRL1, NPSR1, OPRK1 | HSD17B10 3616/4885OPRL1 1/4885OPRM1 14/4885 |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | HRH2, HNMT, HRH3 | HSD17B10 3362/4885OPRL1 1047/4885OPRM1 3326/4885 |
| US-20070072837-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HSD17B10 919/4885OPRL1 49/4885OPRM1 273/4885 |
| US-20030144323-A1 | For treatment of disorders and conditions mediated by the histamine receptor; allergies, sleep disorders, dementia | HRH3, HRH2, HRH4 | HSD17B10 2122/4885OPRL1 82/4885OPRM1 285/4885 |
| US-20040002604-A1 | Phenylalkynes | HRH2, HRH3, HNMT | HSD17B10 919/4885OPRL1 49/4885OPRM1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.